ArticlePLoS pathogens2025
A single amino acid substitution in Fibronectin Binding protein A (FnBPA) governs Staphylococcus aureus virulence via host transglutaminase-mediated fibrin crosslinking.
Article in PLoS pathogens, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Staphylococcus aureus is an opportunistic pathogen that can cause different types of infections, ranging from skin lesions to life threatening diseases. Its ability to evade host immunity and establish persistent infections relies on effective adhesion to host tissues, mainly through interactions between bacterial surface proteins and extracellular matrix (ECM) components such as fibrinogen (Fbg). Here we describe a new pathogenic mechanism where S. aureus uses host transglutaminases to covalently anchor itself to Fbg. Specifically, human Factor XIII (FXIII) activated by S. aureus coagulase von Willebrand factor-binding protein (vWbp) crosslinks the bacterial adhesin Fibronectin Binding Protein A (FnBPA) to fibrin(ogen). Beyond vWbp-activated FXIII, also tissue transglutaminase 2 (TG2) is involved in a similar pathway. Previous biochemical studies showed that Gln103 in the N1 subdomain of FnBPA is the main reactive glutamine residue for FXIII-mediated crosslinking. We demonstrated that FnBPA protein mutants lacking Gln103, substituted with an alanine (Q103A) retained non-covalent Fbg binding via the classical Dock, Lock, and Latch mechanism, but failed to form covalent complexes. Furthermore, a mutant bacterial strain expressing FnBPA Q103A showed impaired incorporation into fibrin matrices. Also, in vivo experiments demonstrated that in a murine infection model the same Q103A mutant was less virulent, formed smaller dermonecrotic lesions and had lower bacterial loads than the wild-type strain. Importantly, also TG2, expressed in various tissues and upregulated during inflammation, crosslinks FnBPA to Fbg only in presence of Gln103, highlighting the broader physiological relevance of this mechanism beyond coagulation sites. Together, these results show a new virulence strategy where S. aureus uses vWbp to hijack host transglutaminase activity, stabilizing bacterial-host protein complexes through covalent FnBPA-Fbg interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.